$HAIAF
Healthcare AI Acquisition Corp. Stock $haiaf

$haiaf Overview Financials Valuation SEC Filings Company Website

2025 Q1 Form 10-K Financial Statement

#000147793225001399 Filed on March 03, 2025

Income Statement

Concept	2025 Q1	2024 Q4	2024
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses
YoY Change
Operating Profit			-$670.8K
YoY Change			-42.59%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net			$727.7K
YoY Change			-86.76%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings			$56.84K
YoY Change			-98.69%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding	5.790M shares	5.790M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2025 Q1	2024 Q4	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents		$212.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses		$0.00
Receivables
Other Receivables
Total Short-Term Assets		$994.6K
YoY Change		469058.96%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets		$4.665M
YoY Change		-29.2%
TOTAL ASSETS
Total Short-Term Assets		$994.6K
Total Long-Term Assets		$4.665M
Total Assets		$5.659M
YoY Change		-14.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses		$1.149M
YoY Change		376.52%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$2.272M
YoY Change		282.91%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities		$2.272M
Total Long-Term Liabilities
Total Liabilities		$2.394M
YoY Change		109.06%
SHAREHOLDERS EQUITY
Retained Earnings		-$1.613M
YoY Change		-3.4%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		-$1.400M
YoY Change
Total Liabilities & Shareholders Equity		$5.659M
YoY Change		-14.11%

Cashflow Statement

Concept	2025 Q1	2024 Q4	2024
OPERATING ACTIVITIES
Net Income			$56.84K
YoY Change			-98.69%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities			-$446.1K
YoY Change			11.24%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities			$446.1K
YoY Change
NET CHANGE
Cash From Operating Activities			-$446.1K
Cash From Investing Activities
Cash From Financing Activities			$446.1K
Net Change In Cash			$0.00
YoY Change			-100.0%
FREE CASH FLOW
Cash From Operating Activities			-$446.1K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001848861
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity File Number EntityFileNumber	001-41145
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-12-31
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity Registrant Name EntityRegistrantName	HEALTHCARE AI ACQUISITION CORP.
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1585450
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	8 The Green
CY2024	dei	Entity Address Address Line2 EntityAddressAddressLine2	Ste 15614
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Dover
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	DE
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19810
CY2024	dei	City Area Code CityAreaCode	917
CY2024	dei	Local Phone Number LocalPhoneNumber	446-0469
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	true
CY2024Q2	dei	Entity Public Float EntityPublicFloat	6687916	usd
CY2025Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5789786	shares
CY2024	dei	Auditor Name AuditorName	Bush & Associates CPA LLC
CY2024	dei	Auditor Location AuditorLocation	Henderson, Nevada
CY2024	dei	Auditor Firm AuditorFirmId	6797
CY2024Q4	us-gaap	Cash Cash	212	usd
CY2023Q4	us-gaap	Cash Cash	212	usd
CY2024Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	994405	usd
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	usd
CY2024Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	0	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	0	usd
CY2024Q4	us-gaap	Assets Current AssetsCurrent	994617	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	212	usd
CY2024Q4	us-gaap	Investments And Cash InvestmentsAndCash	4664536	usd
CY2023Q4	us-gaap	Investments And Cash InvestmentsAndCash	6588790	usd
CY2024Q4	us-gaap	Assets Assets	5659153	usd
CY2023Q4	us-gaap	Assets Assets	6589002	usd
CY2024Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1148721	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	241064	usd
CY2024Q4	haia	Promissory Note Related Party Current PromissoryNoteRelatedPartyCurrent	675751	usd
CY2023Q4	haia	Promissory Note Related Party Current PromissoryNoteRelatedPartyCurrent	216449	usd
CY2024Q4	haia	Amount Due To Related Parties Current AmountDueToRelatedPartiesCurrent	447174	usd
CY2023Q4	haia	Amount Due To Related Parties Current AmountDueToRelatedPartiesCurrent	135745	usd
CY2024Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2271646	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	593258	usd
CY2024Q4	haia	Warrant Liability Non Current WarrantLiabilityNonCurrent	122675	usd
CY2023Q4	haia	Warrant Liability Non Current WarrantLiabilityNonCurrent	552035	usd
CY2024Q4	us-gaap	Liabilities Liabilities	2394321	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1145293	usd
CY2024Q4	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital	4664536	usd
CY2023Q4	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital	6588790	usd
CY2024Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	212913	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	524380	usd
CY2024Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1613156	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1670000	usd
CY2024Q4	us-gaap	Stockholders Equity StockholdersEquity	-1399704	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1145081	usd
CY2024Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5659153	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6589002	usd
CY2024	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	670810	usd
CY2023	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1168501	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-670810	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-1168501	usd
CY2024	us-gaap	Investment Income Interest InvestmentIncomeInterest	298294	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	4734543	usd
CY2024	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-429360	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-762335	usd
CY2024	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	727654	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5496878	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	56844	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	4328377	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-8710136	usd
CY2023	haia	Conversion Of Class B Shares To Class A Shares Amount ConversionOfClassBSharesToClassASharesAmount	0	usd
CY2023	haia	Re Measurement Of Class A Ordinary Shares Subject To Possible Redemption ReMeasurementOfClassAOrdinarySharesSubjectToPossibleRedemption	-4834542	usd
CY2023	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	524380	usd
CY2023	haia	Forgive Of Deferred Underwriter Discount ForgiveOfDeferredUnderwriterDiscount	7546840	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	4328377	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1145081	usd
CY2024	haia	Re Measurement Of Class A Ordinary Shares Subject To Possible Redemption ReMeasurementOfClassAOrdinarySharesSubjectToPossibleRedemption	-311467	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	56844	usd
CY2024Q4	us-gaap	Stockholders Equity StockholdersEquity	-1399704	usd
CY2024	us-gaap	Profit Loss ProfitLoss	56844	usd
CY2023	us-gaap	Profit Loss ProfitLoss	4328377	usd
CY2024	haia	Interest Earned On Investments Held In Trust InterestEarnedOnInvestmentsHeldInTrust	298294	usd
CY2023	haia	Interest Earned On Investments Held In Trust InterestEarnedOnInvestmentsHeldInTrust	4734543	usd
CY2024	haia	Change In Warrant Liability ChangeInWarrantLiability	-429360	usd
CY2023	haia	Change In Warrant Liability ChangeInWarrantLiability	-762335	usd
CY2024	haia	Increase Decrease In Prepaid Assets IncreaseDecreaseInPrepaidAssets	0	usd
CY2023	haia	Increase Decrease In Prepaid Assets IncreaseDecreaseInPrepaidAssets	-222834	usd
CY2024	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-86748	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	212410	usd
CY2024	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	311430	usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	302194	usd
CY2024	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	0	usd
CY2023	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	30000	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-446128	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-401063	usd
CY2024	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	446128	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	446128	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	0	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-401063	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	212	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	401275	usd
CY2024Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	212	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	212	usd
CY2024	haia	Accretion Of Class A Ordinary Shares Subject To Possible Redemption AccretionOfClassAOrdinarySharesSubjectToPossibleRedemption	311467	usd
CY2023	haia	Accretion Of Class A Ordinary Shares Subject To Possible Redemption AccretionOfClassAOrdinarySharesSubjectToPossibleRedemption	4834543	usd
CY2024	haia	Deferred Offering Costs Included In Accrued Offering Costs And Expenses DeferredOfferingCostsIncludedInAccruedOfferingCostsAndExpenses	994405	usd
CY2023	haia	Deferred Offering Costs Included In Accrued Offering Costs And Expenses DeferredOfferingCostsIncludedInAccruedOfferingCostsAndExpenses	0	usd
CY2024	haia	Deferred Underwriting Payable Forgave DeferredUnderwritingPayableForgave	0	usd
CY2023	haia	Deferred Underwriting Payable Forgave DeferredUnderwritingPayableForgave	7546840	usd
CY2024	haia	Administrative Service Fee Forgave By Related Party Charge To Additional Paid In Capital AdministrativeServiceFeeForgaveByRelatedPartyChargeToAdditionalPaidInCapital	0	usd
CY2023	haia	Administrative Service Fee Forgave By Related Party Charge To Additional Paid In Capital AdministrativeServiceFeeForgaveByRelatedPartyChargeToAdditionalPaidInCapital	177095	usd
CY2024	haia	Deferred Offering Costs Assumed By Related Party Charge To Additional Paid In Capital DeferredOfferingCostsAssumedByRelatedPartyChargeToAdditionalPaidInCapital	0	usd
CY2023	haia	Deferred Offering Costs Assumed By Related Party Charge To Additional Paid In Capital DeferredOfferingCostsAssumedByRelatedPartyChargeToAdditionalPaidInCapital	347285	usd
CY2024	haia	Redemption Of Shares From Marketable Securities Held In Trust Account RedemptionOfSharesFromMarketableSecuritiesHeldInTrustAccount	2235721	usd
CY2023	haia	Redemption Of Shares From Marketable Securities Held In Trust Account RedemptionOfSharesFromMarketableSecuritiesHeldInTrustAccount	221294640	usd
CY2024	haia	Promissory Loan From Sponsor For Extension PromissoryLoanFromSponsorForExtension	13173	usd
CY2023	haia	Promissory Loan From Sponsor For Extension PromissoryLoanFromSponsorForExtension	100000	usd
CY2024Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust	2500000	usd
CY2024	haia	Threshold Minimum Aggregate Fair Market Value As Percentage Of Assets Held In Trust Account ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount	0.80	pure
CY2024	haia	Threshold Percentage Of Outstanding Voting Securities Of Target To Be Acquired By Post Transaction Company To Complete Business Combination ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination	0.50	pure
CY2024	haia	Threshold Period From Closing Of Initial Public Offering Company Is Obligated To Complete Business Combination ThresholdPeriodFromClosingOfInitialPublicOfferingCompanyIsObligatedToCompleteBusinessCombination	P18M
CY2024	haia	Number Of Business Days To Redeem Shares Upon Completion Of Initial Business Combination NumberOfBusinessDaysToRedeemSharesUponCompletionOfInitialBusinessCombination	two business days
CY2024Q2	us-gaap	Assets Held In Trust AssetsHeldInTrust	50000	usd
CY2023Q3	us-gaap	Stockholders Equity Other Shares StockholdersEquityOtherShares	1146276	shares
CY2023Q3	haia	Amount Removed From Trust Account AmountRemovedFromTrustAccount	12302385	usd
CY2023Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10.73
CY2023Q3	haia	Common Stock Shares Redemption CommonStockSharesRedemption	591851	shares
CY2023Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	6352029	usd
CY2024Q4	us-gaap	Cash Cash	212	usd
CY2023Q4	us-gaap	Cash Cash	212	usd
CY2024Q4	haia	Working Capital WorkingCapital	1277029	usd
CY2023Q4	haia	Working Capital WorkingCapital	593046	usd
CY2023Q2	us-gaap	Assets Held In Trust AssetsHeldInTrust	15000	usd
CY2024Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.033
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The preparation of financial statement in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p>
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p>
CY2024Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q4	us-gaap	Cash Cash	212	usd
CY2023Q4	us-gaap	Cash Cash	212	usd
CY2024Q4	haia	Cash And Investments Held In Trust Account CashAndInvestmentsHeldInTrustAccount	4664536	usd
CY2023Q4	haia	Cash And Investments Held In Trust Account CashAndInvestmentsHeldInTrustAccount	6588790	usd
CY2024Q4	haia	Stockholder Equity Other Shares StockholderEquityOtherShares	19824274	shares
CY2023Q4	haia	Stockholder Equity Other Shares StockholderEquityOtherShares	1146276	shares
CY2024Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10.54
CY2023Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10.73
CY2023Q2	us-gaap	Amount Of Regulatory Costs Not Yet Approved AmountOfRegulatoryCostsNotYetApproved	208992255	usd
CY2023Q3	us-gaap	Amount Of Regulatory Costs Not Yet Approved AmountOfRegulatoryCostsNotYetApproved	12302385	usd
CY2024Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares	192664	shares
CY2024Q4	haia	Payment To Shareholders Per Share PaymentToShareholdersPerShare	11.60
CY2024Q4	haia	Payment To Shareholders To Cover Tax Obligation PaymentToShareholdersToCoverTaxObligation	2235721	usd
CY2024	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC Topic 815, “Derivatives and Hedging—Contracts in Entity’s Own Equity” (“ASC 815”). The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. In accordance with ASC Topic 825 “Financial Instruments,” offering costs attributable to the issuance of the derivative warrant liabilities have been allocated based on their relative fair value of total proceeds and are recognized in the statement of operations as incurred.</p>
CY2024Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	21906161	shares
CY2024Q4	haia	Dissolution Expense DissolutionExpense	100000	usd
CY2024Q3	haia	Onsecured Promissory Note Issued OnsecuredPromissoryNoteIssued	350000	usd
CY2024Q4	us-gaap	Unsecured Debt UnsecuredDebt	100000	usd
CY2024	us-gaap	Notes Issued1 NotesIssued1	52692	usd
CY2024	us-gaap	Interest Expense Other Short Term Borrowings InterestExpenseOtherShortTermBorrowings	459302	usd
CY2024	haia	Amount Interest Bearing And Unsecured Promissory Note AmountInterestBearingAndUnsecuredPromissoryNote	1500000	usd
CY2024Q4	haia	Accrued Sponsor Fees AccruedSponsorFees	177095	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	177095	usd
CY2024Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	994405	usd
CY2024	haia	Cash Underwriting Discount Percentage CashUnderwritingDiscountPercentage	0.020	pure
CY2024	haia	Underwriter Cash Discount UnderwriterCashDiscount	4312480	usd
CY2024	haia	Deferred Underwriter Discount Amount DeferredUnderwriterDiscountAmount	7546840	usd
CY2023Q2	haia	Deferred Underwriter Discount Amount DeferredUnderwriterDiscountAmount	7546840	usd
CY2024Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	21906161	shares
CY2024Q4	haia	Percentage Of Gross Proceeds On Equity Proceeds PercentageOfGrossProceedsOnEquityProceeds	0.60	pure
CY2024Q4	haia	Class Of Warrant Or Right Adjustment Of Exercise Price Of Warrants Or Rights Percent Based On Market Value And Newly Issued Price ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice	1.15	pure
CY2024Q4	haia	Class Of Warrant Or Right Adjustment Of Redemption Price Of Warrants Or Rights Percent Based On Market Value And Newly Issued Price One ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPriceOne	1.80	pure
CY2024Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001

Files In Submission

Name	View Source	Status
0001477932-25-001399-index-headers.html	Edgar Link	pending
0001477932-25-001399-index.html	Edgar Link	pending
0001477932-25-001399.txt	Edgar Link	pending
0001477932-25-001399-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
haia-20241231.xsd	Edgar Link	pending
haia_10k.htm	Edgar Link	pending
haia_ex21.htm	Edgar Link	pending
haia_ex311.htm	Edgar Link	pending
haia_ex312.htm	Edgar Link	pending
haia_ex321.htm	Edgar Link	pending
haia_ex322.htm	Edgar Link	pending
haia_ex42.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
haia-20241231_cal.xml	Edgar Link	unprocessable
haia-20241231_pre.xml	Edgar Link	unprocessable
haia-20241231_def.xml	Edgar Link	unprocessable
haia-20241231_lab.xml	Edgar Link	unprocessable
haia_10k_htm.xml	Edgar Link	completed
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HAIAF
Healthcare AI Acquisition Corp. Stock $haiaf

2025 Q1 Form 10-K Financial Statement

#000147793225001399 Filed on March 03, 2025

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HAIAF Healthcare AI Acquisition Corp. Stock $haiaf

2025 Q1 Form 10-K Financial Statement

#000147793225001399 Filed on March 03, 2025

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HAIAF
Healthcare AI Acquisition Corp. Stock $haiaf